Clinical Trial Update: A Study of SNP-ACTH (1-39) Gel in Patients With Primary Membranous Nephropathy [Phase 3]

View source ↗

Summary

Cerium Pharmaceuticals reports a Phase 3 clinical trial of SNP-ACTH (1-39) Gel for primary membranous nephropathy, currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Membranous Nephropathy

Drugs mentioned

• SNP-ACTH (1-39) Gel (ACTH (1-39) gel)

Snippet

Sponsor: Cerium Pharmaceuticals, Inc. | Conditions: Primary Membranous Nephropathy | Phase 3 | Status: RECRUITING